Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2268 - An innovative Dendritic Cell Vaccine for Castration-Resistant Prostate Cancer Patients: radiological PFS results

Date

10 Sep 2017

Session

Poster display session

Topics

Clinical Research;  Immunotherapy;  Prostate Cancer

Presenters

Harm Westdorp

Authors

H. Westdorp1, I.M. van Oort2, G. Schreibelt3, A.L. de Goede4, N. Mehra5, C.A. Hulsbergen-van de Kaa6, C.G. Figdor3, F. Witjes2, E. Aarntzen7, R.D.M. Mus7, M. Gotthardt7, J.O. Barentsz7, I..J.M. de Vries1, W.R. Gerritsen5

Author affiliations

  • 1 Medical Oncology And Tumor Immunology, Radboud University Medical Centre Nijmegen, 6525GA - Nijmegen/NL
  • 2 Urology, Radboudumc, Nijmegen/NL
  • 3 Tumor Immunology, Radboud University Medical Centre Nijmegen, 6525GA - Nijmegen/NL
  • 4 Pharmacy, Radboudumc, Nijmegen/NL
  • 5 Medical Oncology, Radboud University Medical Centre Nijmegen, Nijmegen/NL
  • 6 Pathology, Radboudumc, Nijmegen/NL
  • 7 Radiology And Nuclear Medicine, Radboudumc, Nijmegen/NL
More

Resources

Abstract 2268

Background

Castrate-resistant prostate cancer (CRPC) is a deadly disease which warrants new therapies. Clinical evidence supports a beneficial effect of immune stimulation in CRPC patients shown by sipuleucel-T. Dendritic cells (DC) are the immune system’s professional antigen presenting cells. The use of new DC subpopulations could improve their outcome.

Methods

In this phase II trial, HLA-A*02.01 positive chemo-naive CRPC patients were randomly assigned (1:1:1) to myeloid DC (mDC), plasmacytoid DC (pDC) or combined mDC + pDC vaccinations. Patients had disease progression by rising PSA or increase in measurable disease by RECIST 1.1 and PCWG2. Patients received DC vaccination loaded with the tumor-associated antigens MUC1, NY-ESO-1, and MAGE-C2. Radiological responses were assessed on 68Ga-PSMA PET-CT scan (incl. RECIST 1.1), iron oxide-enhanced MRI scan of lymph nodes (nano-MRI) and MRI bones. Primary endpoint is the immunological response post-DC vaccination. Main secondary endpoints are safety and feasibility, radiological PFS and PSA response.

Results

We present the early clinical results of the first 12 patients. Patients were assigned to mDC vaccinations (n=5), pDC vaccinations (n=5) or combined mDC + pDC vaccinations (n=2). All vaccine types were tolerated well (grade 1-2 toxicity in 4/12 patients). Most importantly, 8 of 12 patients (67%) showed radiological stable disease after 6 months using PSMA PET-CT scanning confirmed by (nano-) MRI scans. In patients with at least 9 months follow-up (n=6), 5 still show stable disease. Radiological stable patients showed a trend to an increased PSA doubling time (PSAdt); prevaccination PSAdt was 8.7 months (95% CI: 4,0-13,3) vs. 19.9 months (95% CI: 10,4-29,3) at 6 months.

Clinical responses in the first twelve CRPC patients treated with blood-derived DC vaccinations.

Blood-derived DC treated patient^

Treatment at screening

GS

Disease sites

Side effects#

Radiological response$ at 6 mo

Baseline PSA (ug/l)

PSA after

3 mo (ug/l)

PSA after

6 mo (ug/l)

PSAdt at inclusion (mo)

PSAdt calculated after 6 mo

Ongoing DC vac after 6 mo

1

2

3

4

5

6

7

8

9

10

11

12

LHRH + AA

LHRH

LHRH + AA

LHRH + AA

SO + AA

LHRH + AA

LHRH + AA

LHRH + AA

LHRH

LHRH + AA

LHRH

LHRH + AA

4+5

4+4

3+4

4+3

3+4

5+5

4+5

5+5

5+4

4+5

3+4

4+4

Local, bone

Local

Local

LN, bone

LN

LN

Local, bone

Local, LN, bone

Local, LN

Local, LN, bone

Bone

Local, LN, bone

None

None

Hematoma

UTI

Diarrhea

FLS, fatigue

None

None

None

None

Dizziness

None

SD

SD

SD

PD

SD

SD

SD

PD

SD

SD

PD

PD

5.8

4.6

10

39

4.8

6.3

3.6

8.4

5.7

17

38

41

10

4.3

11

100

10

16

3.8

26

7.3

19

120

42

13

5.0

13

170

21

11

5.0

36

7.2

19

430

70

6.0

6.5

23.9

2.1

3.2

2.9

10.5

2.3

7.3

8.9

3.9

3.0

7.3

27.2

16.5

2.0*

3.2

29.8

12.5

1.8

16.9

45.4

1.6

8.8

YES

YES

YES

NO

YES

YES

YES

NO

YES

YES

NO

NO

AA: oral anti-androgen therapy (bicalutamide in nine patients and abiraterone plus dexamethason in one patient); DC: dendritic cells; GS: Gleason score; FLS: flu-like symptoms; LHRH: luteinizing hormone-releasing hormone; LN: lymph nodes; mo: months; PD: progressive disease; PSAdt: prostate-specific antigen doubling time; SD: stable disease; SO: subcapsular orchidectomy; UTI: urinary tract infection; vac: vaccinations.

^ vaccination with mDC (patients 1-5), pDC (patients 6-10) or combined mDC + pDC (patient 11 and 12).

# only vaccine-related Common Terminology Criteria for Adverse Events grade 1-2 side effects were seen. The UTI was related to progressive LN metastases.

$ radiological responses were assessed on advanced imaging with 68Ga-PSMA PET CT scans, nano-MRIs and MRI bones using RECIST 1.1 and PCWG2 criteria.

* radiological and biochemical progression of disease was already present after 4 months, whereupon DC vaccinations were stopped.

Conclusions

Innovative DC vaccination is feasible and safe in early CRPC patients. Clinical results of the first 12 vaccinated patients showed radiological stable disease in 67% of patients at 6 months.

Clinical trial identification

ClinicalTrials.gov Identifier: NCT02692976. First received: September 30, 2015

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.